Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 482-200-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
The test substance was judged negative because the number of revertant colonies for the test substance treatment groups in all test strains was less than twice that of the negative control regardless of a presence or absence of S9 mix.
The number of revertant colonies in the positive controls were above two times that of the negative control. The test results showed that the numbers of revertant colonies in the negative control and positive controls were within the range of the historical data at Hita laboratory. It was also confirmed that the test system was free from bacterial contamination, which indicates the test results to be valid.
The ability of FP-100 to induce chromosomal aberrations was investigated by using Chinese hamster lung fibroblasts (CHL/IU cells). Acetome was used as a solvent.
Based on the results of the cell growth inhibition test, the doses in the chromosomal aberration test were set at 1250, 2500 and 5000 µg/ml in the short term treatment without S9 and in the 24 hour continuous treatment, and 158, 500, 1580 and 5000µg/ml in the short term treatment with S9 mix.
In the chromosomal aberration test, the doses for the observation were selected at 1250, 2500 and 5000 µg/ml in the short term treatments without S9 and in the 24 hour continuous treatment, and at 500, 1580 and 5000µg/ml for the short term treatment with S9 mix. In observation, the frequencies of cells with structural aberrations and numerical cells were scored.
As a result of observation of the specimens, frequencies of cells with structural aberrations or numerical aberration cells showed below 5% at all dosse of the test substance in the short term treatments without and with S9 mix and 24 hours continuous treatment, therefore the structural aberrations and numerical aberations were judged to be negative.
On the other hand the freauencies of cells with structural aberrations and numerical aberration cells in the negative control treated for acetone showed below 5% and the frequencies of cells with structural aberrations in the positive controls treated with mitomycin C and cyclophosphamide showed abvoe 20% indicating the proper performance of the present study.
It is concluded that FP-100 does not possess an ability to induce chromosomal abberations under the present test conditions.
From the above results, it was concluded that FP-100 had no ability to induce mutations under the present test conditions.
Short description of key information:
The test substance was judged negative because the number of revertant colonies for the test substance treatment groups in all test strains was less than twice that of the negative control regardless of a presence or absence of S9 mix.
In each treatment method, the frequencies of cells with chromosomal aberrations did not fluctuate markedly between two culture dishes, and the frequencies of cells with chromosomal aberrations were below 5% in the negative controls, and the frequencies of cells with structural aberrations excluding gaps were over 20% with positive controls, indicating that the present study was appropriately performed.
In the short-term treatments without and with S9 mix and the continuous treatment, the frequencies of cells with structural aberration cells were below 5% at all observation doses of the test substance. Consequently, the structural aberration and the numerical aberration were judged to be negative.
Based on the above results, it was considered that FP-100 did not possess an abiltiy to induce chromosomal aberrations under the present test conditions.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Negative study result
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.